Following these phases, retatrutide may hit pharmacies by late 2027 or 2028
The absence of leg cramps from official labeling does not definitively rule out a connection, as post-marketing experience sometimes reveals adverse effects not detected in pre-approval trials due to sample size limitations, duration of follow-up, or patient population differences
In 2022, Wegovy received FDA approval to treat adolescent obesity based on the STEP TEENS study
Drug interactions: Orforglipron's CYP3A-mediated metabolism raises the potential for drug-drug interactions with strong CYP3A inhibitors and inducers
Additionally, GLP-1 RAs may alleviate symptoms of related adverse reactions
Earlier Fullness Smaller meals may feel more satisfying, and fullness may last longer after eating